Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Radiochemotherapy with Erbitux plus Temozolomide in Primary Therapy of Glioblastoma Multiforme
2005-003911-63Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and temozolomide in glioblastoma (GBM), sponsored by Heidelberg University. Primary endpoint: toxicity. Started Oct 2005; status: completed.
02
Drugs
cetuximabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2005-003911-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003911-63.